Hey orris
Hey! How's it going? What can I help you with today?
What is the management for pre eclampsia
Reading File
Finding Sources
Searching PubMed
"pre-eclampsia" AND management
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
I have enough comprehensive information. Let me now compile the full answer.
Management of Pre-eclampsia
(Based on Creasy & Resnik's Maternal-Fetal Medicine and Harrison's Principles of Internal Medicine 22E)
1. Diagnosis Recap (for context)
Pre-eclampsia = new-onset hypertension (BP ≥140/90 mmHg on 2 occasions ≥4 hours apart) after 20 weeks gestation, with:
- Proteinuria (≥300 mg/24h, protein:creatinine ratio ≥0.3), OR
- In absence of proteinuria: thrombocytopenia (<100,000/µL), elevated liver enzymes (>2x normal), new renal insufficiency (creatinine >1.1 mg/dL), pulmonary edema, or new cerebral/visual disturbances
Severe features = any of:
- BP ≥160/110 mmHg (on 2 occasions ≥4 hours apart)
- New cerebral or visual disturbances
- Pulmonary edema
- Persistent epigastric/RUQ pain unresponsive to medication
- Liver enzymes >2x normal
- Thrombocytopenia (platelets <100,000/µL)
- Progressive renal insufficiency (creatinine >1.1 mg/dL or doubling of creatinine)
2. Core Philosophy of Management
Three principles guide therapy:
- Delivery is always appropriate therapy for the mother, but not always for the fetus. The disease is completely reversible after delivery. The clinical challenge is balancing maternal safety against fetal prematurity.
- Treating the signs (hypertension, proteinuria) does not treat the disease. Antihypertensives do not alter the underlying pathophysiology (vasospasm, poor perfusion). The goal of BP control is purely to prevent stroke, not to cure the condition.
- Careful antepartum observation is essential because disease progression rate is unpredictable.
3. Delivery Timing (Definitive Treatment)
| Scenario | Recommendation |
|---|---|
| Preeclampsia without severe features at ≥37 weeks | Deliver |
| Preeclampsia without severe features at <37 weeks | Expectant management with close monitoring until 37 weeks |
| Preeclampsia with severe features at ≥34 weeks | Deliver |
| Preeclampsia with severe features at <34 weeks | Expectant management only in a tertiary hospital setting if stable |
Indications to deliver before 34 weeks (even with expectant management plan):
- Unrelenting maternal symptoms
- Developing laboratory abnormalities (HELLP, worsening renal/hepatic dysfunction)
- Severe BP refractory to medical treatment
- Severe fetal growth restriction or placental abruption concerns
4. Expectant Management (Preterm)
Preeclampsia without severe features (<37 weeks):
- Frequent monitoring of BP, symptoms, labs (CBC, LFTs, creatinine, uric acid)
- Fetal surveillance (non-stress tests, biophysical profile, growth scans)
- Limited physical activity
- Antihypertensives are NOT routinely used (no proven fetal benefit; goal is only to prevent maternal stroke)
Preeclampsia with severe features (<34 weeks - inpatient at tertiary centre):
- Continuous maternal and fetal monitoring
- Corticosteroids (betamethasone) for fetal lung maturity if <34 weeks
- Magnesium sulfate for seizure prophylaxis
- Antihypertensives for BP ≥160/105 mmHg
5. Antihypertensive Therapy
When to treat: BP persistently ≥160 mmHg systolic or ≥105-110 mmHg diastolic for >15 minutes. This is a hypertensive emergency requiring prompt treatment to prevent intracranial hemorrhage/stroke.
Target BP: 135-145/95-100 mmHg (avoid over-treatment as it can compromise uteroplacental perfusion due to already-reduced plasma volume)
First-line agents for acute severe hypertension:
| Drug | Route | First Dose | Repeat | Max | Notes |
|---|---|---|---|---|---|
| Labetalol | IV | 10-20 mg | 20 mg, 40 mg, 80 mg | 300 mg/day | Contraindicated in asthma, CHF, heart block |
| Hydralazine | IV or IM | 5 mg | 5-10 mg every 20-40 min | - | Direct arteriolar dilator; may cause headache, reflex tachycardia |
| Nifedipine | PO | 10 mg | 10-20 mg q30 min, then q2-6h | 20 mg/dose | Calcium channel blocker; reflex tachycardia |
Oral agents (labetalol, nifedipine extended-release) are used once BP is acutely controlled for maintenance.
6. Magnesium Sulfate (Seizure Prophylaxis / Eclampsia Prevention)
- Given intrapartum and for 24-48 hours postpartum
- Used in preeclampsia with severe features to prevent eclampsia (seizures)
- Reduces the risk of eclampsia by ~50% vs. placebo
- Loading dose: 4-6 g IV over 15-20 minutes
- Maintenance: 1-2 g/hour IV infusion
- Monitor for toxicity: loss of patellar reflexes (first sign), respiratory depression, cardiac arrest
- Antidote: Calcium gluconate 1 g IV
Magnesium sulfate may reduce fetal heart rate variability - further evaluation is needed if this occurs.
7. Mode of Delivery
- Vaginal delivery is preferred and should be attempted in most cases
- Induction of labor is appropriate if the cervix is favorable
- Cesarean is indicated in cases of marked hepatic capsular distention (risk of liver rupture) or if vaginal delivery is not imminent and maternal instability is present
- Regional (epidural/spinal) anesthesia is appropriate but requires careful volume management to avoid hypotension and reduced uteroplacental perfusion
- General anesthesia/deep sedation is not a rational method to control or prevent eclampsia
8. HELLP Syndrome
- A severe variant of preeclampsia (Hemolysis, Elevated Liver enzymes, Low Platelets)
- Hypertension and proteinuria may not be present
- Management is the same as preeclampsia with severe features: delivery is definitive treatment
9. Postpartum Care
- Pre-eclampsia begins to abate after delivery but BP monitoring must continue 24-72 hours postpartum (and up to 6 weeks)
- Magnesium sulfate continued for 24-48 hours postpartum
- Women with a history of pre-eclampsia carry a significantly elevated lifetime risk of cardiovascular disease, chronic hypertension, CKD, and diabetes - appropriate follow-up and counselling is essential
10. Prevention (for Future Pregnancies)
- Low-dose aspirin (81 mg/day) starting at 12-28 weeks (ideally before 16 weeks) is recommended for women at high risk of pre-eclampsia (prior history, chronic hypertension, multifetal gestation, renal disease, diabetes)
- Calcium supplementation may be beneficial in populations with low dietary calcium intake
Sources:
- Creasy & Resnik's Maternal-Fetal Medicine: Principles and Practice, Chapters 45 (Management of Preeclampsia, pp. 1068-1090)
- Harrison's Principles of Internal Medicine, 22E (2025), Section on Preeclampsia Treatment
This is a shared conversation. Sign in to Orris to start your own chat.